. Author manuscript; available in PMC: 2011 Jan 11.

Published in final edited form as: Transplantation. 2009 Mar 15;87(5):704–710. doi: 10.1097/TP.0b013e318195c474

Table 4.

Grades III – IV acute GVHD, according to combined patient IL10/−592 and donor IL10RB/c238 genotypes, comparing results with unrelated versus related recipients

Genotype		Overall unrelated transplant (n=639)^a			HLA-matched unrelated transplant (n=311)^a			HLA-identical sibling transplant (n=953)^b
Patient IL10/−592	Donor IL10RB	Incidence of GVHD ^c	Trend hazard ratiod	Trend P valued	Incidence of GVHD ^c	Trend hazard ratio^d	Trend P value^d	Incidence of GVHD ^c	Trend hazard ratio^d	Trend P value^d
C/C	A/A	37% (189)			37% (97)			22% (292)
	A/G	34% (154)	1.0	0.82	36% (72)	1.0	0.87	22% (183)	1.0	0.81
	G/G	47% (30)	(0.8–1.3)		38% (16)	(0.7–1.4)		24% (29)	(0.8–1.4)
A/C	A/A	40% (105)			40% (48)			22% (190)
	A/G	37% (97)	0.9	0.46	28% (46)	0.6	0.09	11% (141)	0.5	0.004
	G/G	31% (16)	(0.6–1.3)		30% (10)	(0.3–1.1)		8% (37)	(0.3–0.8)
A/A	A/A	35% (23)			33% (9)			15% (33)
	A/G	12% (17)	1.1	0.83	0% (8)	0.7	0.74	9% (32)	0.4	0.07
	G/G	63% (8)	(0.5–2.6)		40% (5)	(0.1–4.2)		0% (16)	(0.1–1.2)

Among the 655 patients with paired patient/donor samples available, 320 pairs were matched for HLA-A, B, C and DRB1 alleles. Grading of acute GVHD was not available for 16 patients.

results from a cohort of 953 recipients with HLA-identical sibling donors (12–13).

cumulative incidence of grades III–IV acute GVHD at day 100. Numbers of cases are indicated in parentheses.

The trend hazard ratios and trend P values were analyzed within each stratum of patients IL10/−592 genotype. 95% confidence intervals were indicated in the parentheses.